Genfit (GNFT) Stock Forecast, Price Target & Predictions
GNFT Stock Forecast
Genfit stock forecast is as follows: an average price target of $13.00 (represents a 206.60% upside from GNFT’s last price of $4.24) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
GNFT Price Target
The average price target for Genfit (GNFT) is $13.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $13.00. This represents a potential 206.60% upside from GNFT's last price of $4.24.
GNFT Analyst Ratings
According to 1 Wall Street analysts, Genfit's rating consensus is 'Buy'. The analyst rating breakdown for GNFT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Genfit Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Ed Arce | H.C. Wainwright | $13.00 | $5.03 | 158.45% | 206.60% |
The latest Genfit stock forecast, released on Sep 23, 2024 by Ed Arce from H.C. Wainwright, set a price target of $13.00, which represents a 158.45% increase from the stock price at the time of the forecast ($5.03), and a 206.60% increase from GNFT last price ($4.24).
Genfit Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $13.00 | $13.00 |
| Last Closing Price | $4.24 | $4.24 | $4.24 |
| Upside/Downside | -100.00% | 206.60% | 206.60% |
In the current month, the average price target of Genfit stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Genfit's last price of $4.24. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 23, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Genfit's last stock rating was published by H.C. Wainwright on Sep 23, 2024. The company gave GNFT a "Buy" rating, the same as its previous rate.
Genfit Financial Forecast
Genfit Revenue Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | $29.94M | $48.05M | $76.76M |
| High Forecast | $29.94M | $48.05M | $76.76M |
| Low Forecast | $29.94M | $48.05M | $76.76M |
| # Analysts | 1 | 1 | 1 |
| Surprise % | - | - | - |
Genfit's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. GNFT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Genfit EBITDA Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| EBITDA | - | - | - |
| Avg Forecast | $-21.34M | $-34.25M | $-54.72M |
| High Forecast | $-21.34M | $-34.25M | $-54.72M |
| Low Forecast | $-21.34M | $-34.25M | $-54.72M |
| Surprise % | - | - | - |
undefined analysts predict GNFT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Genfit's previous annual EBITDA (undefined) of $NaN.
Genfit Net Income Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| Net Income | - | - | - |
| Avg Forecast | $84.85M | $18.96M | $46.79M |
| High Forecast | $84.85M | $18.96M | $46.79M |
| Low Forecast | $84.85M | $18.96M | $46.79M |
| Surprise % | - | - | - |
Genfit's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GNFT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Genfit SG&A Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| SG&A | - | - | - |
| Avg Forecast | $213.70M | $342.91M | $547.81M |
| High Forecast | $213.70M | $342.91M | $547.81M |
| Low Forecast | $213.70M | $342.91M | $547.81M |
| Surprise % | - | - | - |
Genfit's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to GNFT last annual SG&A of $NaN (undefined).
Genfit EPS Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| EPS | - | - | - |
| Avg Forecast | $1.41 | $0.31 | $0.78 |
| High Forecast | $1.41 | $0.31 | $0.78 |
| Low Forecast | $1.41 | $0.31 | $0.78 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, Genfit's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GNFT previous annual EPS of $NaN (undefined).
Genfit Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics | $1.23 | $8.75 | 611.38% | Buy |
| MOLN | Molecular Partners | $5.42 | $29.00 | 435.06% | Buy |
| AVTE | Aerovate Therapeutics | $2.61 | $13.00 | 398.08% | Hold |
| ANEB | Anebulo Pharmaceuticals | $1.50 | $6.00 | 300.00% | Buy |
| ACRV | Acrivon Therapeutics | $6.44 | $21.83 | 238.98% | Buy |
| FENC | Fennec Pharmaceuticals | $4.72 | $15.75 | 233.69% | Buy |
| GNFT | Genfit | $4.24 | $13.00 | 206.60% | Buy |
| RZLT | Rezolute | $4.86 | $13.50 | 177.78% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| ADAG | Adagene | $2.26 | $5.00 | 121.24% | Buy |
| KROS | Keros Therapeutics | $53.84 | $102.60 | 90.56% | Buy |
| HRMY | Harmony Biosciences | $33.23 | $48.86 | 47.04% | Buy |
| EWTX | Edgewise Therapeutics | $31.98 | $45.00 | 40.71% | Buy |
| JANX | Janux Therapeutics | $46.50 | $61.20 | 31.61% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |